Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
--Transaction forms combined NASDAQ-listed biopharmaceutical company, focused on the discovery, development and commercialization of plasma kallikrein inhibitors for the treatment of hereditary...
-
PALO ALTO, Calif., April 15, 2016 (GLOBE NEWSWIRE) -- Carbylan Therapeutics (NASDAQ:CBYL), a specialty pharmaceutical company, announced today that it has suspended further clinical development of...
-
PALO ALTO, Calif., March 17, 2016 (GLOBE NEWSWIRE) -- Carbylan Therapeutics (NASDAQ:CBYL), a specialty pharmaceutical company focused on the development of novel and proprietary combination...
-
PALO ALTO, Calif., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Carbylan Therapeutics (NASDAQ:CBYL), a specialty pharmaceutical company focused on the development of novel and proprietary combination...
-
PALO ALTO, Calif., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Carbylan Therapeutics (NASDAQ:CBYL), a specialty pharmaceutical company focused on the development of novel and proprietary combination therapies,...
-
PALO ALTO, Calif., Nov. 4, 2015 (GLOBE NEWSWIRE) -- Carbylan Therapeutics (NASDAQ:CBYL), a specialty pharmaceutical company focused on the development of novel and proprietary combination therapies,...
-
PALO ALTO, Calif., Nov. 3, 2015 (GLOBE NEWSWIRE) -- Carbylan Therapeutics (NASDAQ:CBYL), a specialty pharmaceutical company focused on the development of novel and proprietary combination therapies,...
-
PALO ALTO, Calif., Aug. 11, 2015 (GLOBE NEWSWIRE) -- Carbylan® Therapeutics (NASDAQ:CBYL), a specialty pharmaceutical company focused on the development of novel and proprietary combination...
-
PALO ALTO, Calif., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Carbylan Therapeutics (NASDAQ:CBYL), a specialty pharmaceutical company focused on the development of novel and proprietary combination therapies,...
-
PALO ALTO, Calif., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Carbylan Therapeutics (NASDAQ:CBYL), a specialty pharmaceutical company focused on the development of novel and proprietary combination therapies,...